Clinical Trial
The clinical trials of plasmalogens
are proving their excellence.
1. The Effect of Scallop-Derived Plasmalogens on Mild Cognitive Impairment (MCI) and Mild Alzheimer's Disease via Oral Administration
This clinical trial was conducted as a randomized, double-blind, placebo-controlled study.
Participants were randomly assigned to either the Plasmalogen group or the Placebo group. The Plasmalogen group consumed 0.5mg of plasmalogens twice daily, while the Placebo group consumed a placebo without plasmalogens twice daily. The duration of consumption was 24 weeks, during which various tests were conducted before and after intake.
Over 24 weeks of plasmalogen consumption, the Plasmalogen group showed significant improvement in "spatial recall" on the MMSE-J compared to the Placebo group (P=0.003). Additionally, regarding "temporal recall," the Placebo group exhibited decline after 24 weeks, while the Plasmalogen group maintained baseline levels.
In mild cognitive impairment, cognitive functions typically deteriorate in the order of "temporal recall" followed by "spatial recall." In this trial, the Plasmalogen group first improved in "spatial recall," followed by improvement in "temporal recall."
These findings confirm that consumption of plasmalogens for 24 weeks improves both "temporal recall" and "spatial recall."
According to the Wechsler Memory Scale-Revised (WMS-R) results, the group that consumed scallop-derived plasmalogens showed significant memory improvement compared to the placebo group after 24 weeks (p=0.029 for each). Additionally, in mild Alzheimer's disease patients, the plasmalogen group demonstrated significantly higher plasma plasmalogen levels after 24 weeks compared to the placebo group (p=0.016).
These results indicate that administering plasmalogens derived from scallops to Alzheimer's disease patients may lead to symptom improvement.
1. The Effect of Scallop-Derived Plasmalogens on Mild Cognitive Impairment (MCI) and Mild Alzheimer's Disease via Oral Administration
This clinical trial was conducted as a randomized, double-blind, placebo-controlled study.
Participants were randomly assigned to either the Plasmalogen group or the Placebo group. The Plasmalogen group consumed 0.5mg of plasmalogens twice daily, while the Placebo group consumed a placebo without plasmalogens twice daily. The duration of consumption was 24 weeks, during which various tests were conducted before and after intake.
An analysis of MMSE scores in moderate to moderate-severe Alzheimer's patients revealed significant improvements in scores starting from 4 weeks after plasmalogen intake (p<0.001). Subsequently, significant increases were observed at 8 weeks (p<0.01) and 12 weeks (p<0.001). However, no significant changes were observed in moderate Alzheimer's patients up to 12 weeks.
After 12 weeks of plasmalogen intake, a significant improvement of 2 points or more in MMSE scores was observed in 53% of moderate to moderate-severe Alzheimer's patients, while 28% showed improvement in moderate Alzheimer's patients. Cases with no change were 36% in moderate to moderate-severe Alzheimer's patients and 56% in moderate Alzheimer's patients. Considering that cognitive function tends to decline over time in moderate Alzheimer's patients, these findings suggest that plasmalogen intake may help maintain cognitive function.
Overall, the improvement effects of plasmalogens on Alzheimer's disease appear more pronounced in moderate to moderate-severe Alzheimer's patients compared to those with mild cognitive impairment (MCI) or mild Alzheimer's disease.
Clinical trials were conducted at several participating medical institutions to assess the effects on behavioral and psychological symptoms (BPSD) in Alzheimer's patients. The results confirmed significant improvements in symptoms such as hallucinations, depression, agitation, and delusions.
While dementia symptoms often focus on core symptoms like memory impairment and cognitive decline, BPSD can severely impact the quality of life (QOL) for caregivers and family members of Alzheimer's patients. Addressing these symptoms is crucial in dementia treatment and care.
The improvement effects of plasmalogens on BPSD in dementia are highly significant for Alzheimer's treatment. These improvements can provide significant psychological and physical relief to Alzheimer's patients and their families, enhancing their overall quality of life.
Research on the effects of plasmalogens on higher brain functions showed a recovery rate of over 80% in aspects such as facial expressions (smiling) and empathy. Previously thought to be formed by entirely different brain mechanisms, higher brain functions can potentially be improved not only in the hippocampus but also in other brain tissues through the action of plasmalogens.
Additionally, plasmalogens demonstrated significant reductions in various diseases including metabolic syndrome, cardiovascular disease, and depression, which are known risk factors for dementia, not just dementia itself.
After consuming scallop-derived plasmalogens for 12 weeks, significant increases in plasma plasmalogen levels were observed in moderate to mild Alzheimer's patients.
Specifically, both erythrocyte membrane and plasma plasmalogen levels showed significant increases in moderate Alzheimer's patients. Similarly, significant increases in plasma plasmalogen levels were also observed in mild Alzheimer's patients.
1. The Effect of Scallop-Derived Plasmalogens on Mild Cognitive Impairment (MCI) and Mild Alzheimer's Disease via Oral Administration
This clinical trial was conducted as a randomized, double-blind, placebo-controlled study.
Participants were randomly assigned to either the Plasmalogen group or the Placebo group. The Plasmalogen group consumed 0.5mg of plasmalogens twice daily, while the Placebo group consumed a placebo without plasmalogens twice daily. The duration of consumption was 24 weeks, during which various tests were conducted before and after intake.
Specifically, the Plasmalogen group showed significant decreases in scores related to anger-hostility and fatigue-inertia, whereas no significant changes were noted in the Placebo group. These results indicated highly significant differences between the two groups in terms of anger-hostility (P = 0.003) and fatigue-inertia (P = 0.005).
Scores on the Athens Insomnia Scale (indicating higher levels of insomnia) began to decrease in the Plasmalogen group from 2 weeks onwards, showing a significant difference between the two groups (P = 0.07).
When evaluated using the Uchida-Kraepelin test to assess concentration, the Plasmalogen group demonstrated statistically significant improvement in concentration compared to the Placebo group.
In conclusion, consuming plasmalogens has been proven to reduce negative mood, improve sleep, and increase concentration.